Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).
Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).
Mel Greaves (Institute of Cancer Research, London, UK) discusses his proposed theory for the etiology of childhood acute lymphoblastic leukemia, in which early microbial exposure plays a key role (10:21).
This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.
Listen to Fabien Maldonado, from Vanderbilt University Medical Center in Nashville, Tennessee, USA, give his views on the AMPLE trial, which aimed to establish the more effective technique for reducing the number of hospitalization days in patients with malignant pleural effusion.
The phase III GOG 240 trial evaluated bevacizumab in women with advanced cervical cancer - Advisory Board member and lead investigator Krishnansu Tewari outlines the results of the final analysis in this podcast.